Virology

• 

  Publication Venue For

  • Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas..  520:116-126. 2018
  • Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization..  514:106-117. 2018
  • The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis..  512:113-123. 2017
  • The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly.  506:34-44. 2017
  • Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment..  479-480:213-220. 2015
  • Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37-45].  478:155-158. 2015
  • Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37–45].  478:149-152. 2015
  • Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease..  476:196-205. 2015
  • Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes..  475:37-45. 2015
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques..  471-473:81-92. 2014
  • Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence..  462-463:363-376. 2014
  • Analysis of viral microRNA expression by elephant endotheliotropic herpesvirus 1.  454-455:102-108. 2014
  • Analysis of viral microRNA expression by elephant endotheliotropic herpesvirus 1..  454-455:102-108. 2014
  • Persistently adenovirus-infected lymphoid cells express microRNAs derived from the viral VAI and especially VAII RNA.  447:140-145. 2013
  • Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling.  447:240-248. 2013
  • Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.  436:33-48. 2013
  • Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A..  433:220-225. 2012
  • Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection..  412:411-425. 2011
  • In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins.  421:28-33. 2011
  • Analysis of rhesus rhadinovirus microRNAs expressed in virus-induced tumors from infected rhesus macaques..  405:592-599. 2010
  • Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication..  405:234-242. 2010
  • Processing of SeMV polyproteins revisited..  396:106-117. 2010
  • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins..  394:91-98. 2009
  • Characterization of a trimeric MPER containing HIV-1 gp41 antigen.  390:221-227. 2009
  • Stacking interactions of W271 and H275 of SeMV serine protease with W43 of natively unfolded VPg confer catalytic activity to protease..  382:83-90. 2008
  • Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response..  378:272-281. 2008
  • ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells..  379:197-204. 2008
  • Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination..  375:315-320. 2008
  • Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques..  374:322-337. 2008
  • Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system..  374:453-467. 2008
  • Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope..  372:442-456. 2008
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine..  369:153-167. 2007
  • Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens..  367:175-186. 2007
  • A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120..  366:245-262. 2007
  • Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate..  366:84-97. 2007
  • The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains..  364:486-493. 2007
  • Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus..  364:21-27. 2007
  • Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies..  363:79-90. 2007
  • Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge..  362:441-452. 2007
  • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins..  360:218-234. 2007
  • Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells..  358:357-372. 2007
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques..  358:69-78. 2007
  • Recombination in feline lentiviral genomes during experimental cross-species infection.  359:146-151. 2007
  • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses..  353:268-282. 2006
  • Ancestral and consensus envelope immunogens for HIV-1 subtype C..  352:438-449. 2006
  • Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine..  352:285-294. 2006
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype..  348:341-353. 2006
  • Crystal structure of the serine protease domain of Sesbania mosaic virus polyprotein and mutational analysis of residues forming the S1-binding pocket..  346:440-451. 2006
  • Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates..  345:44-55. 2006
  • Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques..  343:246-255. 2005
  • Identification of regions of the Beet mild curly top virus (family Geminiviridae) capsid protein involved in systemic infection, virion formation and leafhopper transmission..  341:257-270. 2005
  • Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs..  340:21-32. 2005
  • Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif..  339:281-288. 2005
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives..  332:623-628. 2005
  • Protein interactions among the vaccinia virus late transcription factors..  329:328-336. 2004
  • Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor..  328:163-168. 2004
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope..  328:74-88. 2004
  • Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564..  324:525-530. 2004
  • Post-transcription cleavage generates the 3' end of F17R transcripts in vaccinia virus..  319:1-11. 2004
  • The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis..  317:263-274. 2003
  • Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements..  311:241-253. 2003
  • The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma..  310:100-108. 2003
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6)..  308:178-190. 2003
  • HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest..  305:371-377. 2003
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model..  294:270-281. 2002
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA..  292:1-5. 2002
  • Expression of the vaccinia virus A2.5L redox protein is required for virion morphogenesis.  300:296-303. 2002
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease..  292:137-149. 2002
  • Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation..  288:175-187. 2001
  • Genetic variation in the 3' non-coding region of dengue viruses..  281:75-87. 2001
  • An in vitro transcription system that recapitulates equine infectious anemia virus tat-mediated inhibition of human immunodeficiency virus type 1 Tat activity demonstrates a role for positive transcription elongation factor b and associated proteins in the mechanism of Tat activation..  274:356-366. 2000
  • Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis..  273:248-257. 2000
  • Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia..  270:237-249. 2000
  • Canine cyclin T1 rescues equine infectious anemia virus tat trans-activation in human cells..  268:7-11. 2000
  • Glycoprotein B of human herpesvirus 8 is a component of the virion in a cleaved form composed of amino- and carboxyl-terminal fragments..  269:18-25. 2000
  • Analysis of the RNA binding specificity of the human tap protein, a constitutive transport element-specific nuclear RNA export factor..  262:200-209. 1999
  • Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional..  259:7-19. 1999
  • The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins..  256:173-179. 1999
  • Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex..  255:337-346. 1999
  • A 43-nucleotide RNA cis-acting element governs the site-specific formation of the 3' end of a poxvirus late mRNA..  255:190-204. 1999
  • Retroviruses as model systems for the study of nuclear RNA export pathways..  249:203-210. 1998
  • Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle..  242:90-98. 1998
  • Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles..  241:251-259. 1998
  • Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors..  236:316-327. 1997
  • Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences..  234:253-260. 1997
  • Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4..  231:231-238. 1997
  • Genome nucleotide lengths that are divisible by six are not essential but enhance replication of defective interfering RNAs of the paramyxovirus simian virus 5..  232:145-157. 1997
  • Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting..  230:265-274. 1997
  • Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35)..  226:13-21. 1996
  • Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa..  225:274-281. 1996
  • The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope..  224:415-426. 1996
  • Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha..  223:132-147. 1996
  • Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev..  222:423-429. 1996
  • A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier..  219:220-227. 1996
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1..  219:407-416. 1996
  • The mode of death of pig kidney cells infected with cowpox virus is governed by the expression of the crmA gene..  217:384-391. 1996
  • Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins..  209:347-357. 1995
  • Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators..  206:1150-1154. 1995
  • Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection..  205:82-92. 1994
  • The role of Nef in the replication cycle of the human and simian immunodeficiency viruses..  205:1-6. 1994
  • A single stem-loop structure within the HTLV-1 Rex response element is sufficient to mediate Rex activity in vivo..  204:144-152. 1994
  • Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor..  204:343-356. 1994
  • Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent..  202:940-948. 1994
  • Sequence requirements for Rev multimerization in vivo..  202:186-194. 1994
  • Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice..  201:147-151. 1994
  • Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: Mutational analysis of a primary HIV-1 isolate.  200:623-631. 1994
  • Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.  200:236-245. 1994
  • Generation of reovirus core-like particles in cells infected with hybrid vaccinia viruses that express genome segments L1, L2, L3, and S2..  197:726-731. 1993
  • Increased expression of alpha 4 beta 1 and alpha 5 beta 1 integrins on HTLV-I-infected lymphocytes..  197:778-781. 1993
  • Localization of the african swine fever virus attachment protein p12 in the virus particle by immunoelectron microscopy.  193:460-465. 1993
  • Alterations within pp59v-rel-containing protein complexes following the stimulation of REV-T-transformed lymphoid cells with zinc..  188:765-777. 1992
  • The eukaryotic translation initiation factor 4E is not modified during the course of vaccinia virus replication..  188:934-937. 1992
  • The 9-kDa hydrophobic protein encoded at the 3′ end of the porcine transmissible gastroenteritis coronavirus genome is membrane-associated.  186:676-683. 1992
  • Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus..  182:635-643. 1991
  • Distinct DNA targets for trans-activation by HTLV-1 tax and adenovirus E1A..  182:156-167. 1991
  • Transcription of the terminal loop region of vaccinia virus DNA is initiated from the telomere sequences directing DNA resolution..  181:716-720. 1991
  • Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain?.  178:560-567. 1990
  • Functions of the auxiliary gene products of the human immunodeficiency virus type 1..  178:1-5. 1990
  • Sequence and expression analysis of potential nonstructural proteins of 4.9, 4.8, 12.7, and 9.5 kDa encoded between the apike and membrane protein genes of the bovine coronavirus.  177:488-495. 1990
  • Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site.  176:296-301. 1990
  • Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors..  175:600-604. 1990
  • Transcription of orthopoxvirus telomeres at late times during infection..  175:69-80. 1990
  • Fine structure mapping and phenotypic analysis of five temperature-sensitive mutations in the second largest subunit of vaccinia virus DNA-dependent RNA polymerase..  174:60-69. 1990
  • Synthesis and processing of equine herpesvirus type 1 glycoprotein 14..  173:638-646. 1989
  • Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus..  172:262-273. 1989
  • Inhibitory effects of vesicular stomatitis virus on cellular and influenza viral RNA metabolism and protein synthesis..  172:274-284. 1989
  • Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide..  171:205-213. 1989
  • The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively..  169:293-304. 1989
  • High-level synthesis of biologically active reovirus protein sigma 1 in a mammalian expression vector system..  167:601-612. 1988
  • Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization..  167:433-441. 1988
  • The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1..  167:31-37. 1988
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus..  166:533-541. 1988
  • Nucleotide sequence of the envelope protein genes of a highly virulent, neurotropic strain of Newcastle disease virus..  165:291-295. 1988
  • The coenrichment of stem cells, prothymocytes, and stromal elements with ecotropic retrovirus-producing cells from the bone marrow of leukemia-prone AKR mice..  162:354-361. 1988
  • Replication of the murine cytomegalovirus genome: structure and role of the termini in the generation and cleavage of concatenates..  162:98-107. 1988
  • Tandemly repeated sequences are present at the ends of the DNA of raccoonpox virus..  161:45-53. 1987
  • Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect..  160:372-378. 1987
  • The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice..  157:387-396. 1987
  • Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic..  155:726-731. 1986
  • Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens..  152:459-465. 1986
  • Influence of amino acids encoded in the 3' open reading frame of the SV40 early region on transformation and antigenicity of large T antigen..  150:361-372. 1986
  • Isolation of cowpox virus A-type inclusions and characterization of their major protein component..  149:174-189. 1986
  • Conservation of the 3′ terminal nucleotide sequences of Ebola and Marburg virus.  149:251-254. 1986
  • Properties of mouse leukemia viruses: XX. Variation of AKR substrains in response to antibody therapy.  150:247-251. 1986
  • Base mutations in the terminal noncoding regions of the genome of vesicular stomatitis virus isolated from persistent infections of L cells.  140:249-256. 1985
  • RNA sequence and transcriptional properties of the 3′ end of the Newcastle disease virus genome.  145:203-212. 1985
  • Interactions of plus and minus strand leader RNAs of the New Jersey serotype of vesicular stomatitis virus with the cellular La protein..  135:65-73. 1984
  • Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus..  135:105-117. 1984
  • Genome structure and expression of a defective interfering mutant of the killer virus of yeast.  137:20-31. 1984
  • Structure of the genome of equine herpesvirus type 3..  132:352-367. 1984
  • Transcription in mouse embryo cells permissively infected by murine cytomegalovirus..  131:247-254. 1983
  • Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain)..  129:94-106. 1983
  • Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells..  126:688-672. 1983
  • Sequential synthesis of small capped RNA transcripts in vitro by vesicular stomatitis virus..  125:206-218. 1983
  • Cloning of the terminal loop of vaccinia virus DNA..  124:215-217. 1983
  • Intracellular cleavage of an SSV coded gag-related protein..  123:229-234. 1982
  • Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing)..  121:307-319. 1982
  • The sequence at the termini of four genes of the three reovirus serotypes..  121:320-326. 1982
  • Properties of the genome of equine herpesvirus type 3..  120:18-32. 1982
  • Superimmunity: characterization of a new gene in the immunity region of P1..  120:360-375. 1982
  • XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells..  119:68-81. 1982
  • Association of 3' terminal RNA sequences with avian leukosis viruses causing a high incidence of osteopetrosis..  116:163-180. 1982
  • Identification of a 20,000-dalton protein in SSV-transformed nonproducer cells..  115:401-405. 1981
  • Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein..  114:124-131. 1981
  • Detection of a transformation-specific glycopeptide in SSV-infected cells..  112:642-650. 1981
  • Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71..  111:568-578. 1981
  • Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins..  111:270-274. 1981
  • The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface..  108:147-155. 1981
  • Nature of the 3'-terminal sequences of the plus and minus strands of the S1 gene of reovirus serotypes 1, 2 and 3..  105:41-51. 1980
  • The plus strand of reovirus gene S2 is identical with its in vitro transcript..  105:282-286. 1980
  • Evidence that the src gene product of Rous sarcoma virus is membrane associated..  101:25-40. 1980
  • Further characterization of the oncornavirus inactivating factor in normal mouse serum..  98:20-34. 1979
  • Properties of mouse leukemia viruses. XVI. Suppression of spontaneous fetal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp 71..  93:159-174. 1979
  • Effects of the src gene product on microfilament and microtubule organization in avian and mammalian cells infected with the same temperature-sensitive mutant of Rous sarcoma virus..  92:201-210. 1979
  • B-MuX: a unique murine C-type virus containing the "env" gene of xenotropic viruses and the "gag" gene of the ecotropic virus..  90:255-264. 1978
  • Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus..  90:241-254. 1978
  • Normal chicken cells (chf-) express a surface antigen which cross-reacts with determinants of the major envelope glycoprotein (gp85) of avian myeloblastosis virus..  86:205-216. 1978
  • An analysis of type-C retrovirus polypeptides and their associations in the virion..  84:19-31. 1978
  • Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein..  83:207-210. 1977
  • Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection..  79:1-13. 1977
  • Polypeptides of endogenous avian C-type viruses: their detection in the plasma membrane of normal and infected cells..  78:511-521. 1977
  • Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias..  75:401-418. 1976
  • Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice..  75:74-87. 1976
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice..  75:88-101. 1976
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis..  75:102-112. 1976
  • Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated..  71:346-351. 1976
  • Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus..  71:169-184. 1976
  • A comparison of the extents of methylation of vesicular stomatitis virus messenger RNA..  69:364-367. 1976
  • Polypeptides of mammalian oncornaviruses. IV. Structural components of murine leukemia virus released as soluble antigens in cell culture..  68:550-555. 1975
  • Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses..  67:234-241. 1975
  • Viral glycoprotein synthesis under conditions of glucosamine block in cells transformed by avian sarcoma viruses..  66:347-355. 1975
  • The initial nucleotide sequence of DNA transcribed from avian myeloblastosis virus 70 S RNA by RNA-dependent DNA polymerase..  65:163-172. 1975
  • Comparative chemical properties of avian oncornavirus polypeptides..  64:339-348. 1975
  • Immunological properties of avian oncornavirus polypeptides..  64:349-357. 1975
  • Poly (A) sequences of vaccinia virus messenger RNA: nature, mode of addition and function during translation in vitra and in vivo..  63:1-14. 1975
  • Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity..  63:48-59. 1975
  • Polypeptides of mammalian oncornaviruses. II. Characterization of a murine leukemia virus polypeptide (p15) bearing interspecies reactivity..  63:48-59. 1975
  • A proposed nomenclature for the virion proteins of oncogenic RNA viruses..  60:595-600. 1974
  • Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses..  56:565-579. 1973
  • Gene A of X174. 1. Isolation and identification of its products..  50:381-387. 1972
  • Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope..  47:551-566. 1972
  • Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core..  47:567-578. 1972
  • Properties of mouse leukemia viruses. II. Isolation of viral components..  47:210-228. 1972
  • Polypeptides of avian RNA tumor viruses. 3. Purification and identification of a DNA synthesizing enzyme..  45:298-302. 1971
  • Isolation and characterization of two group-specific antigens from feline leukemia virus..  44:73-82. 1971
  • Studies on the reproductive and cell-converting abilities of avian sarcoma viruses..  43:427-441. 1971
  • Size differences among the high molecular weight RNA's of avian tumor viruses..  43:214-222. 1971
  • Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis..  42:1097-1112. 1970
  • Observations on bluetongue virus in the salivary glands of an insect vector, Culicoides variipennis..  30:127-133. 1966
  • Corrigendum to "Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies" [Virology 363 (2007) 79-90] (DOI:10.1016/j.virol.2007.01.015).  368:431. 2007
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. 2002